Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

55.11USD
21 Aug 2017
Change (% chg)

-- (--)
Prev Close
$55.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
589,614
52-wk High
$67.74
52-wk Low
$35.84

AGIO.O

Chart for AGIO.O

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $2,666.84
Shares Outstanding(Mil.): 48.39
Dividend: --
Yield (%): --

Financials

  AGIO.O Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -6.31 -- --
ROI: -46.41 2.83 14.89
ROE: -67.30 5.09 16.13

BRIEF-Agios posts Q2 loss per share $1.78‍​

* Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​

Aug 08 2017

FDA approves leukemia treatment developed by Celgene, Agios

The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's oral treatment for acute myeloid leukemia (AML) patients with a rare genetic mutation.

Aug 01 2017

UPDATE 2-FDA approves leukemia treatment developed by Celgene, Agios

* Oppenheimer estimates Idhifa sales of $1.4 bln in 2021 (Adds pricing details, analyst comments and share move)

Aug 01 2017

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

Aug 01 2017

FDA approves leukemia treatment developed by Celgene, Agios

Aug 1 The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

Aug 01 2017

BRIEF-Agios appoints David Scadden to the board of directors

* Agios appoints David Scadden to the board of directors Source text for Eikon: Further company coverage:

May 31 2017

BRIEF-Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals

* Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals for next-generation sequencing oncology companion diagnostic in cholangiocarcinoma

May 18 2017

BRIEF-Agios Pharmaceuticals to present updated clinical data from PKR activator AG-348

* Agios Pharmaceuticals Inc says to present updated clinical data from PKR activator AG-348 at EHA Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Agios Pharmaceuticals Inc Q1 net loss was $66.2 million

* Agios Pharmaceuticals Inc - net loss for quarter ended March 31, 2017 was $66.2 million, compared to a net loss of $23.2 million for quarter ended March 31, 2016

May 04 2017

BRIEF-Agios announces closing of over-allotment option in public offering

* Agios announces closing of over-allotment option in public offering

Apr 28 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.76 +0.09
Novartis AG (NOVN.S) CHF80.45 +0.50
Roche Holding Ltd. (ROG.S) CHF243.30 +2.90
Roche Holding Ltd. (RO.S) CHF246.70 +2.50
Sanofi SA (SASY.PA) €82.10 +0.20
AstraZeneca plc (AZN.L) 4,426.83 +8.84
GlaxoSmithKline plc (GSK.L) 1,491.38 +11.88
Eli Lilly and Co (LLY.N) $77.38 +0.31
Shire PLC (SHP.L) 3,671.00 +58.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates